You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Dual Molecular/Targeting Therapy for PanCa

    SBC: SYNERGENE THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Approximately 30,000 people in the United States are diagnosed each year with pancreatic Cancer (PanCa). Over 90% of these will die of the disease making PanCa one of the most devastating human malignancies. The current 5-year survival rate of less than 4% has changed little in the last 20 years despite improvements in therapy including the introduction of chem ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  2. Chaperone-based tumor therapy delivered by viral vectors

    SBC: VIRRX, INC            Topic: N/A

    DESCRIPTION (provided by applicant): The efficacy of molecular chaperones as adjuvants for the induction of anti-tumor immunity has been demonstrated in many laboratories over the last two decades. Similarly, the exploration of the therapeutic use of poxviruses in cancer treatment has a long and diverse history. These findings have led us to hypothesize that poxviruses would be an efficient and e ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  3. Biologically-inspired low light integrated vision systems

    SBC: Centeye, Inc.            Topic: AF12BT03

    ABSTRACT: Our objective is to develop a vision system for a micro air vehicle (MAV) or other robotic system that allows it to operate in extremely low light levels, including in zero light conditions and without reliance on GPS. We propose building two systems. The first system will operate primarily in the visible and NIR domain and utilize silicon based photoreceptor circuits. This system will ...

    STTR Phase II 2014 Department of DefenseAir Force
  4. Tiptuximab Immunotherapeutic for Cancer

    SBC: Medical Guidance Systems LLC            Topic: NCI

    ? DESCRIPTION (provided by applicant): Poor prognosis cancers such as lung cancer, glioblastoma, pancreatic cancer and others have 3 year survival rates that range from 1%-15%. Recent advancements in the development of therapeutic antibodies haveshown promise in other cancers such as breast, head and neck, and colon cancer. The limitations in antibody development are the paucity of cancer ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum

    SBC: DXDISCOVERY INC            Topic: NIAID

    DESCRIPTION provided by applicant The number of Lyme disease cases in the US has been recently estimated by the CDC at cases year This is major public health concern Currently available diagnostics rely on detection of the antibody response serology to Borrelia burgdorferi the causative agent of Lyme disease However serological tests are not accurate during the early stages of Ly ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Prediction and Measurement of the Carbon Build-Up in Film-Cooled Rocket Engines

    SBC: SIERRA ENGINEERING, INC.            Topic: AF15AT21

    ABSTRACT: Sierra Engineering Inc. (Sierra) believes that existing chemical kinetic models can be efficiently incorporated into commercial CFD codes to predict the mixing, pyrolysis, soot formation and carbon deposition within film cooled rocket engines. During this Phase I STTR effort we will demonstrate that this analysis capability is practical and that we can generate appropriate model validati ...

    STTR Phase I 2015 Department of DefenseAir Force
  8. New Assays for Expression Profiling of MicroRNAs

    SBC: Nawgen, LLC            Topic: 172

    DESCRIPTION provided by applicant MicroRNAs miRNAs are involved in many diverse biological processes and a single miRNA can modulate the expression of hundreds of gene targets Changes in miRNA expression could have profound biological impacts leading to a variety of human diseases To date most miRNA expression profiling studies have relied on microarrays or high throughput RNA sequencing ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Rational design of small interfering RNA for genome-wide target knockdown

    SBC: Nawgen, LLC            Topic: 172

    DESCRIPTION provided by applicant RNA interference RNAi is a small RNA guided gene silencing process within living cells The RNAi technique is widely used in both biological research and clinical applications because it has the ability to knockdown essentially any gene of interest However one major unresolved issue in RNAi studies is non specific gene silencing It is well known that in ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government